Clinical trials
Glucocorticoid clinical trials
Below are recruiting glucocorticoid clinical trials, each written for real people, not researchers. We’re tracking 45 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07869511Recruiting
Steroid injection behind the eye for light-damage to the retina
This study tests whether a steroid injection behind the eye (a retrobulbar injection) can help people whose retina (the light-sensing layer at the back of the eye) has been damaged by looking at a strong light source, like a laser or bright flash. The treatment aims to reduce swelling and vision problems that can follow such an injury.
Hangzhou, ZhejiangAges 6 years+ - NCT07746180RecruitingPhase 2
Obinutuzumab and low-dose steroids for new kidney disease
This study tests a new combination treatment for people newly diagnosed with a type of kidney inflammation linked to ANCA-associated vasculitis. The treatment combines a targeted medication (obinutuzumab) with a low dose of steroids, aiming to control the disease with fewer side effects.
BeijingAges 18 years+ - NCT06697535RecruitingPhase 2
Study of JYP0061 for acute NMOSD attacks
This trial tests a new medication called JYP0061 for people with NMOSD who are currently experiencing a sudden worsening of symptoms (acute attack). It aims to see if the drug can help control the attack and improve outcomes.
Changsha, HunanAges 18–65 - NCT06654596Recruiting
Telitacicept for IgA nephropathy
This study tests a new medicine called telitacicept for people with IgA nephropathy, a kidney disease that causes protein in the urine. The goal is to see if it safely reduces kidney damage.
ShanghaiAges 18–70 - NCT02719314Recruiting
Study bone loss from steroid use in people with inflammatory disease
This study looks at how steroid medicines (called glucocorticoids) affect bone strength in people with long-term inflammatory rheumatic conditions or psoriasis. It may help improve how doctors check and manage osteoporosis risk and bone metabolism over time.
BerlinAges 18 years+ - NCT07152366RecruitingPhase 4
Hormone and tetuzumab for active thyroid eye disease
This trial tests a new sequence of hormone therapy followed by a targeted drug (tetuzumab) for people with moderate to severe thyroid eye disease that is still active after steroid treatment didn't help enough.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06781944RecruitingPhase 3
Obinutuzumab vs standard treatment for membranous nephropathy
This trial tests a new antibody drug (obinutuzumab) against a standard treatment (cyclophosphamide plus steroids) for people with a kidney condition called primary membranous nephropathy that causes protein leakage. The goal is to see which treatment better reduces protein loss and protects kidney function.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06468709RecruitingPhase 4
Preventing recurrence of high-risk type 1 AIP
This trial studies a treatment to prevent recurrence in people with type 1 autoimmune pancreatitis (AIP) who are at high risk. It looks at how well the treatment works and whether it can keep the disease from coming back.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06395883Recruiting
Steroids and Your Bones in Joint Disease
This study looks at how steroids affect bone health in people with inflammatory joint diseases like rheumatoid arthritis. Researchers will track markers in your blood to see if short-term steroid use impacts your bones.
DrammenAges 25–90 - NCT05789030Recruiting
Treating IgG4-related disease with mild steroid starts
This trial is studying treatment plans for people with IgG4-related disease that affects a surface (superficial) organ area. It focuses on people who are newly diagnosed or have come back and who need to start or continue steroid medicine at a low dose.
BeijingAges 18–75 - NCT05207358RecruitingPhase 4
Lower steroid use in active lupus kidney inflammation
This trial looks at whether people with proliferative lupus nephritis can use less steroid medicine while still controlling kidney inflammation. It may help reduce steroid side effects, while testing a carefully monitored treatment plan.
BucharestAges 18–80 - NCT07748624RecruitingPhase 2
Testing a new drug for people with VEXAS
This study tests an investigational drug called arumakimig (MAS825) in people with VEXAS, a rare genetic condition that causes inflammation. The trial checks if the drug helps control symptoms and improve quality of life.
Yokohama, KanagawaAges 18 years+ - NCT07719140RecruitingPhase 4
Lower steroid dose study for children with lupus nephritis
This trial tests whether a lower starting dose of steroids can control kidney inflammation in children with lupus nephritis. It aims to reduce side effects while still treating the disease effectively.
Beijing, Beijing MunicipalityAges 6–18 - NCT06689254RecruitingPhase 2
Testing mifepristone for hard-to-treat PTSD in Dutch adults
This study tests a new medicine (mifepristone) to see if it helps people with PTSD that hasn't improved after standard treatments. You must be fluent in Dutch and have tried at least two PTSD treatments, including trauma-focused therapy.
Amsterdam, North HollandAges 18 years+ - NCT06730308RecruitingPhase 2
Steroids with chemoradiation for thymoma that can't be removed
This trial tests if adding a steroid (methylprednisolone) to standard chemotherapy and radiation helps people with thymoma that cannot be fully removed by surgery or has come back. The goal is to see if this combination works better at controlling the disease.
Guanzhou, GuangdongAges 18–75 - NCT07547930RecruitingPhase 2
Tofacitinib for Steroid-Resistant Thyroid Eye Disease
This study tests whether tofacitinib, a new type of immune-modulating medication, can help people with moderate-to-severe thyroid eye disease (Graves' orbitopathy) whose eyes haven't improved with standard steroid treatments. The goal is to reduce eye swelling, bulging, and inflammation that affects daily life.
Xiamen, FujianAges 18–75 - NCT07542314RecruitingPhase 4
Gene therapy for Duchenne muscular dystrophy
This study is checking how safe and effective ELEVIDYS, a gene therapy for Duchenne muscular dystrophy, is when used in everyday clinics. It will help doctors understand more about the treatment's real-world effects and provide care for those who receive it.
Houston, TexasAges 4 years+ - NCT07478003RecruitingPhase 3
Early steroid for severe heart attacks before reaching the hospital
This study tests whether giving a high dose of a steroid medication (glucocorticoid) early, before reaching the hospital, can help people having a severe type of heart attack called STEMI. If you are having this specific heart attack and meet the criteria, receiving this medication might improve your recovery.
AalborgAges 18 years+ - NCT06824714Recruiting
Predicting blood vessel damage in large vessel vasculitis
This study uses PET and MRA scans to predict damage to large blood vessels in people who have or may have large vessel vasculitis (LVV). It aims to find at-risk patients early so they can get better care. You'll need to be willing to have both scans and come back for long-term check-ups.
Nanjing, JiangsuAges 18 years+ - NCT07340463RecruitingPhase 2
Biologics vs standard therapy for lupus kidney disease
This trial tests two biologic drugs (belimumab or telitacicept) compared to a standard treatment (mycophenolate mofetil) for people with active lupus nephritis. The goal is to see if biologics work better at controlling kidney inflammation over 6 months.
Nanjing, JiangsuAges 14–65 - NCT07285889RecruitingPhase 1/Phase 2
Jaktinib as first treatment for acute graft-versus-host disease
This trial tests a new pill called jaktinib for people who develop moderate to severe acute graft-versus-host disease (aGVHD) after a stem cell transplant. The goal is to see if adding jaktinib to standard steroid therapy can better control the disease.
Hangzhou, ZhejiangAges 18 years+ - NCT07245732RecruitingPhase 4
Steroid pills vs. shots for rheumatoid arthritis flares
This trial compares steroid pills to steroid shots for controlling sudden worsening of rheumatoid arthritis symptoms. It aims to find which method works better and is easier for you.
Toronto, OntarioAges 18 years+ - NCT07213375RecruitingPhase 2/Phase 3
High-dose steroid to reduce pain after lung surgery
This trial tests if a high dose of dexamethasone (a steroid) can lower pain after keyhole lung surgery. If you are having planned keyhole lung surgery for a lobe or segment, you may be eligible.
Copenhagen, CopenhagenAges 18 years+ - NCT07206537Recruiting
Vitamin K2 to prevent steroid bone loss in children
This study tests whether vitamin K2 can help prevent bone loss caused by steroid treatment in children with nephrotic syndrome. If your child meets the requirements, taking vitamin K2 may protect their bones while they receive steroids.
CairoAges 1–16
Hear when a new Glucocorticoid trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for glucocorticoid?
- Yes. Clin2 currently lists 45 recruiting glucocorticoid studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a glucocorticoid trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a glucocorticoid trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.